🇺🇸 FDA
Pipeline program

METHOTREXATE , MYCOPHENOLIC ACID , AZATHIOPRINE , Tavneos 10 mg hard capsules, CYCLOPHOSPHAMIDE , -, RITUXIMAB, Placebo for AMG 569

20220159

Approved small_molecule active

Quick answer

METHOTREXATE , MYCOPHENOLIC ACID , AZATHIOPRINE , Tavneos 10 mg hard capsules, CYCLOPHOSPHAMIDE , -, RITUXIMAB, Placebo for AMG 569 for Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is a Approved program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).

Program details

Company
Amgen Technology (Ireland) UC
Indication
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials